Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...

Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an ...

Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from ...

By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...

The CEO of the company that makes Olympic and Wegovy was on Capitol Hill this week—asked by senators why popular diabetes and weight loss drugs are so much pricer in the U.S. compared to other ...

Ozempic, first approved in China to treat diabetes in 2021, is often referred to as the “internet celebrity weight-loss drug”. Its use there has soared, as it has almost everywhere. Weight ...